The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Executive Summary
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
You may also be interested in...
Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
Another Blow To Aduhelm As Biogen Withdraws EU Filing
Biogen has withdrawn its filing of the Alzheimer’s drug before the EMA could reject it for the second time, perhaps hoping it could return with better data.